DOCSLIB.ORG

HA Drug Formulary External List V16.5 210522 (Dated 210512)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HA Drug Formulary External List V16.5 210522 (Dated 210512) HOSPITAL AUTHORITY DRUG FORMULARY (v16.5 - w.e.f. 22 May 2021) drugs newly added to each category are highlighted in "yellow" (1) The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand. (2) Some drugs may appear in more than one category due to different formulations and/or indications. (3) The "Special" drugs will be prescribed as clinically indicated based on the specified indications. (4) Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed in the HA Drug Formulary. Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net 1 GASTRO-INTESTINAL SYSTEM 腸胃科藥物 1.1 DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE ALUMINIUM / MAGNESIUM HYDROXIDE AND SIMETHICONE ALUMINIUM HYDROXIDE CHARCOAL ACTIVATED DIMETHYLPOLYSILOXANE GAVISCON (OR EQUIV) MAGNESIUM TRISILICATE MYLANTA (OR EQUIV) ANTISPASMODICS AND OTHER DRUGS ALTERING GUT 1.2 MOTILITY HYOSCINE MEBEVERINE OTILONIUM BROMIDE PEPPERMINT OIL PROPANTHELINE 1.3 ANTISECRETORY DRUGS AND MUCOSAL PROTECTANTS BISMUTH SUBSALICYLATE DEXLANSOPRAZOLE FAMOTIDINE ESOMEPRAZOLE MISOPROSTOL LANSOPRAZOLE PANTOPRAZOLE OMEPRAZOLE RABEPRAZOLE PANTOPRAZOLE RANITIDINE RANITIDINE SUCRALFATE 1.4 ACUTE DIARRHOEA DIOCTAHEDRAL SMECTITE RACECADOTRIL LOPERAMIDE 1.5 CHRONIC BOWEL DISORDERS BUDESONIDE ADALIMUMAB INFLIXIMAB BUDESONIDE (RECTAL) INFLIXIMAB USTEKINUMAB MESALAZINE USTEKINUMAB VEDOLIZUMAB MESALAZINE (SUPP/ENEMA) VEDOLIZUMAB PREDNISOLONE (FOAM/ENEMA) SULPHASALAZINE 1.6 LAXATIVES AGIOCUR (OR EQUIV) MACROGOL AGIOLAX (OR EQUIV) BISACODYL BISACODYL (SUPP) DOCUSATE FLEET (OR EQUIV) FLEET PHOSPHO-SODA BUFFERED SALINE GLYCEROL LACTULOSE METAMUCIL (OR EQUIV) NORMACOL PLUS (OR EQUIV) PHOSPHO-SODA (OR EQUIV) PICOPREP (OR EQUIV) Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net POLYETHYLENE GLYCOL SENNATOSIDE B 1.7 LOCAL PREPARATIONS FOR ANAL AND RECTAL DISORDERS ANUSOL (OR EQUIV) EURORECTAL FAKTU (OR EQUIV) GLYCERYL TRINITRATE (RECTAL) PHENOL IN ALMOND OIL ULTRAPROCT N (OR EQUIV) 1.9 DRUGS AFFECTING INTESTINAL SECRETIONS CHENODEOXYCHOLIC ACID COMBIZYM (OR EQUIV) URSODEOXYCHOLIC ACID PANCREATIN 2 CARDIOVASCULAR SYSTEM 心臟科藥物 2.1 POSITIVE INOTROPIC DRUGS DIGOXIN MILRINONE 2.2 DIURETICS AMILORIDE EPLERENONE BUMETANIDE DYAZIDE (OR EQUIV) FRUSEMIDE HYDROCHLOROTHIAZIDE INDAPAMIDE MANNITOL MANNITOL + SORBITOL METOLAZONE MODURETIC (OR EQUIV) SPIRONOLACTONE 2.3 ANTI-ARRHYTHMIC DRUGS AMIODARONE DRONEDARONE ATROPINE DISOPYRAMIDE FLECAINIDE MEXILETINE PROCAINAMIDE PROPAFENONE QUINIDINE 2.4 BETA-ADRENOCEPTOR BLOCKING DRUGS ATENOLOL BISOPROLOL BISOPROLOL + HYDROCHLOROTHIAZIDE CARVEDILOL ESMOLOL LABETALOL METOPROLOL NADOLOL PROPRANOLOL SOTALOL 2.5 HYPERTENSION AND HEART FAILURE CAPTOPRIL AMBRISENTAN CLONIDINE AMLODIPINE + VALSARTAN ENALAPRIL BOSENTAN ENALAPRILAT CANDESARTAN HYDRALAZINE DOXAZOSIN LISINOPRIL ILOPROST LOSARTAN IRBESARTAN IRBESARTAN + METHYLDOPA HYDROCHLOROTHIAZIDE LOSARTAN + MINOXIDIL HYDROCHLOROTHIAZIDE NITROPRUSSIDE DIHYDRATE SODIUM MACITENTAN PERINDOPRIL SACUBITRIL + VALSARTAN PHENOXYBENZAMINE SELEXIPAG Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net PHENTOLAMINE SILDENAFIL (REVATIO) PRAZOSIN TELMISARTAN TELMISARTAN + PREDONIUM (OR EQUIV) HYDROCHLOROTHIAZIDE RAMIPRIL VALSARTAN VALSARTAN + TERAZOSIN HYDROCHLOROTHIAZIDE NITRATES, CALCIUM-CHANNEL BLOCKERS, AND OTHER 2.6 ANTIANGINAL DRUGS AMLODIPINE CILOSTAZOL DILTIAZEM GINKGO BILOBA EXTRACT FELODIPINE ER IVABRADINE GLYCERYL TRINITRATE LERCANIDIPINE GLYCERYL TRINITRATE (PATCH) NAFTIDROFURYL OXALATE ISOSORBIDE DINITRATE NIFEDIPINE ISOSORBIDE MONONITRATE OXPENTIFYLLINE NICERGOLINE NIFEDIPINE NIMODIPINE VERAPAMIL 2.7 SYMPATHOMIMETICS ADRENALINE DOBUTAMINE DOPAMINE EPHEDRINE ISOPRENALINE METARAMINOL MIDODRINE NORADRENALINE NOREPINEPHRINE PHENYLEPHRINE 2.8 ANTICOAGULANTS AND PROTAMINE ARGATROBAN APIXABAN RIVAROXABAN ENOXAPARIN DABIGATRAN EPOPROSTENOL EDOXABAN HEPARIN RIVAROXABAN NADROPARIN PROTAMINE SULPHATE SODIUM CITRATE TINZAPARIN WARFARIN 2.9 ANTIPLATELET DRUGS ASPIRIN ABCIXIMAB TICAGRELOR ASPIRIN + GLYCINE CLOPIDOGREL DIPYRIDAMOLE EPTIFIBATIDE PRASUGREL TICAGRELOR STABLE ANGINA, ACUTE CORONARY SYNDROMES, AND 2.10 FIBRINOLYSIS STREPTOKINASE ALTEPLASE TENECTEPLASE UROKINASE 2.11 ANTIFIBRINOLYTIC DRUGS AND HAEMOSTATICS TRANEXAMIC ACID EMICIZUMAB FACTOR IX FACTOR VIIA FACTOR VIII FACTOR VIII INHIBITOR BYPASSING FRACTION PROTHROMBIN COMPLEX CONCENTRATE 2.12 LIPID-REGULATING DRUGS ALIROCUMAB Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net ATORVASTATIN CHOLESTYRAMINE EVOLOCUMAB EZETIMIBE FENOFIBRATE GEMFIBROZIL ROSUVASTATIN SIMVASTATIN 2.13 LOCAL SCLEROSANTS ETHANOLAMINE OLEATE SODIUM TETRADECYL SULPHATE 2.A MISCELLANEOUS (CARDIOVASCULAR SYSTEM) ADENOSINE TRIPHOSPHATE DISODIUM LEVOSIMENDAN CARDIOPLEGIA (OR EQUIV) TRIMETAZIDINE DAFLON 500 (OR EQUIV) TISSEEL KIT (OR EQUIV) UBIDECARENONE 3 RESPIRATORY SYSTEM 呼吸系統藥物 3.1 BRONCHODILATORS AMINOPHYLLINE ACLIDINIUM COMBIVENT (OR EQUIV) ACLIDINIUM + FORMOTEROL IPRATROPIUM GLYCOPYRRONIUM (INH) SALBUTAMOL INDACATEROL SALBUTAMOL (INH) INDACATEROL + GLYCOPYRRONIUM TERBUTALINE OLODATEROL THEOPHYLLINE SALBUTAMOL (INH) SALMETEROL TERBUTALINE (INH) TIOTROPIUM TIOTROPIUM + OLODATEROL UMECLIDINIUM UMECLIDINIUM + VILANTEROL 3.2 CORTICOSTEROIDS BECLOMETHASONE DIPROPIONATE BUDESONIDE (INH) BUDESONIDE (INH) BUDESONIDE + FORMOTEROL CICLESONIDE FLUTICASONE + SALMETEROL FLUTICASONE PROPIONATE (INH) FLUTICASONE + FORMOTEROL FLUTICASONE + VILANTEROL TRELEGY (OR EQUIV) CROMOGLICATE AND RELATED THERAPY AND 3.3 LEUKOTRIENE RECEPTOR ANTAGONISTS MONTELUKAST ROFLUMILAST ANTIHISTAMINES, HYPOSENSITISATION AND ALLERGIC 3.4 EMERGENCIES ACTIFED (OR EQUIV) CETIRIZINE + PSEUDOEPHEDRINE BENRALIZUMAB ACTIFED COMPOUND (OR EQUIV) FEXOFENADINE MEPOLIZUMAB ADRENALINE FEXOFENADINE + PSEUDOEPHEDRINE OMALIZUMAB CETIRIZINE LORATADINE + PSEUDOEPHEDRINE CHLORPHENIRAMINE CYPROHEPTADINE DESLORATADINE DEXCHLORPHENIRAMINE DIPHENHYDRAMINE EPINEPHRINE HYDROXYZINE LORATADINE PROMETHAZINE RESPIRATORY STIMULANTS AND PULMONARY 3.5 SURFACTANTS Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net BERACTANT PORACTANT ALFA 3.6 OXYGEN OXYGEN 3.7 MUCOLYTICS ACETYLCYSTEINE AMBROXOL BROMHEXINE CYCLIDROL 3.8 AROMATIC INHALATIONS BENZOIN COMPOUND TINCTURE 3.9 COUGH PREPARATIONS AMMONIA AND IPECACUANHA COCILLANA (OR EQUIV) CODEINE PHOSPHATE DIPHENHYDRAMINE COMPOUND PHOLCODINE PROMETHAZINE COMPOUND 3.10 SYSTEMIC NASAL DECONGESTANTS PSEUDOEPHEDRINE 3.11 ANTIFIBROTICS NINTEDANIB (OFEV) 3.A MISCELLANEOUS (RESPIRATORY SYSTEM) CAFFEINE LYSOZYME NEOZEP (OR EQUIV) TALC STERILE 4 CENTRAL NERVOUS SYSTEM 中樞神經系統藥物 4.1 HYPNOTICS AND ANXIOLYTICS ALPRAZOLAM BROMAZEPAM BUSPIRONE CHLORAL HYDRATE CHLORDIAZEPOXIDE CHLORMETHIAZOLE DIAZEPAM FLUNITRAZEPAM LORAZEPAM MELATONIN MIDAZOLAM NITRAZEPAM TRIAZOLAM ZOLPIDEM ZOPICLONE 4.2 DRUGS USED IN PSYCHOSES AND RELATED DISORDERS AMISULPRIDE ARIPIPRAZOLE ARIPIPRAZOLE CLOZAPINE BREXPIPRAZOLE PALIPERIDONE CHLORPROMAZINE RISPERIDONE FLUPENTHIXOL FLUPHENAZINE HALOPERIDOL LITHIUM CARBONATE LITHIUM SULPHATE LURASIDONE OLANZAPINE PALIPERIDONE PERICYAZINE PIMOZIDE QUETIAPINE RISPERIDONE SULPIRIDE Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net TRIFLUOPERAZINE ZIPRASIDONE ZUCLOPENTHIXOL 4.3 ANTIDEPRESSANT DRUGS AMITRIPTYLINE AGOMELATINE CITALOPRAM BUPROPION CLOMIPRAMINE DESVENLAFAXINE DEANXIT (OR EQUIV) DULOXETINE DOTHIEPIN ESCITALOPRAM DOXEPIN FLUVOXAMINE FLUOXETINE MILNACIPRAN FLUPENTHIXOL PAROXETINE IMIPRAMINE VENLAFAXINE MIANSERIN VORTIOXETINE MIRTAZAPINE MOCLOBEMIDE NORTRIPTYLINE PAROXETINE SERTRALINE TRAZODONE TRIMIPRAMINE CNS STIMULANTS AND OTHER DRUGS USED FOR 4.4 ATTENTION DEFICIT HYPERACTIVITY DISORDER ATOMOXETINE LISDEXAMFETAMINE METHYLPHENIDATE 4.6 DRUGS USED IN NAUSEA AND VERTIGO BETAHISTINE APREPITANT CINNARIZINE FOSAPREPITANT DIMENHYDRINATE GRANISETRON DIMENHYDRINATE (SUPP) NETUPITANT + PALONOSETRON DOMPERIDONE ONDANSETRON FLUNARIZINE HYOSCINE (PATCH) METOCLOPRAMIDE PROCHLORPERAZINE PROMETHAZINE 4.7 ANALGESICS ALCOHOL ABSOLUTE (INJECTION) BUPRENORPHINE (PATCH) ERENUMAB ASPIRIN DULOXETINE BUPRENORPHINE FENTANYL (PATCH) CAFERGOT (OR EQUIV) GABAPENTIN CARBAMAZEPINE MORPHINE CLONIDINE OXYCODONE CODEINE PHOSPHATE PARACETAMOL DIHYDROCODEINE PREGABALIN METHADONE ZOLMITRIPTAN MORPHINE PARACETAMOL PARACETAMOL (SUPP) PETHIDINE PIZOTIFEN SUMATRIPTAN TRAMADOL 4.8 ANTIEPILEPTICS CARBAMAZEPINE BRIVARACETAM CLOBAZAM GABAPENTIN CLONAZEPAM LACOSAMIDE DIAZEPAM LAMOTRIGINE DIAZEPAM (RECTAL) LEVETIRACETAM ETHOSUXIMIDE OXCARBAZEPINE PARALDEHYDE PERAMPANEL Self-financed item Self-financed item BNF General Drugs Special Drugs With Safety Net Without Safety Net PHENOBARBITONE PREGABALIN PHENYTOIN RUFINAMIDE VALPROATE SODIUM TOPIRAMATE VIGABATRIN 4.9 DRUGS USED IN PARKINSONISM AND RELATED DISORDERS AMANTADINE BOTULINUM TYPE A TOXIN BENZHEXOL PRAMIPEXOLE BENZTROPINE RASAGILINE BROMOCRIPTINE ROPINIROLE ENTACAPONE ROTIGOTINE MADOPAR (OR EQUIV) PIRACETAM SELEGILINE SINEMET (OR EQUIV) STALEVO (OR EQUIV) TETRABENAZINE 4.10 DRUGS USED IN SUBSTANCE DEPENDENCE DISULFIRAM BUPRENORPHINE + NALOXONE NALTREXONE NICOTINE NICOTINE (PATCH) VARENICLINE 4.11 DRUGS FOR DEMENTIA DONEPEZIL DONEPEZIL MEMANTINE GALANTAMINE RIVASTIGMINE RIVASTIGMINE (PATCH) 4.A MISCELLANEOUS (CENTRAL NERVOUS
Load more

Recommended publications
  • Antibiotic Treatment in Inflammatory Bowel Disease: Rifaximin, a New Possible Approach
    European Review for Medical and Pharmacological Sciences 1999; 3: 27-30 Review – Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach P. GIONCHETTI, F. RIZZELLO, A. VENTURI, F. UGOLINI*, M. ROSSI**, P. BRIGIDI**, R. JOHANSSON, A. FERRIERI***, G. POGGIOLI*, M. CAMPIERI Clinica Medica I, Nuove Patologie, Bologna University (Italy) *Istituto di Clinica Chirurgica II, Bologna University (Italy) **Dipartimento di Scienze Farmaceutiche, Bologna University (Italy) ***Direzione Medica Alfa Wassermann, Bologna (Italy) Abstract. – The etiology of inflammatory ported the presence of a breakdown of toler- disease is still unknown, but a body of evidence ance to the normal commensal intestinal flora from clinical and experimental observation indi- in active IBD2-3. Reduction of microflora by cates a role for intestinal microflora in the pathogenesis of this disease. Reduction of mi- antibiotics, bowel rest and fecal diversion de- croflora using antibiotics, bowel rest and fecal creases inflammatory activity in Crohn’s dis- diversion decreases activity in Crohn’s disease ease and to a lesser extent in ulcerative colitis and in ulcerative colitis. Several trials have been (UC). The pathogenetic role of intestinal mi- carried out on the use of antibiotic treatment in croflora is further suggested by the observa- patients with active ulcerative colitis with con- tion that experimental colitis, in germ-free or trasting results. A number of trials have been antibiotic treated animals, is less severe com- carried out using Rifaximin, a non-absorbable broad-spectrum antibiotic, confirming the ab- pared to that inducible in normal animals or sence of systemic bioavalaibility of the drug at times is not inducible at all.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Formulary Additions
    JUNE 2016 FORMULARY ADDITIONS MELOXICAM (MOBIC®) Rationale for Addition: Meloxicam is a once daily NSAID used for the treatment of rheumatoid arthritis and osteoarthritis. Meloxicam will provide another oral NSAID option to Celecoxib for patients who are being discharged home and whose insurance does not cover celecoxib. Adverse Effects: abdominal pain, diarrhea, dyspepsia, flatulence, nausea, edema, influenza-like symptoms, dizziness, headache, rash Contraindications: peri-operative pain in setting of coronary artery bypass graft surgery Drug Interactions: other NSAIDS, antiplatelet agents, calcium polysterene sulfonate, cyclosporine, digoxin, lithium, methotrexate, vancomycin, vitamin K antagonist, corticosteroids Dosage & Administration: meloxicam 7.5 mg PO daily, some patients my experience some benefit by increasing to 15 mg PO daily Renal Impairment: not recommended in patients with renal function ≤ 20 mL/min Dosage Form & Cost: meloxicam 7.5 mg tablet $0.02/day meloxicam 15 mg $0.03/day IVABRADINE (CORLANOR®) *Restrictions*: restricted to cardiology only for initiation of therapy Rationale for Addition: Ivabradine blocks the funny current leading to a reduction in heart rate at the sinoatrial node. Ivabradine is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable symptomatic chronic heart failure with LVEF ≤ 35% who are in sinus rhythm with resting heart rate (HR) ≥ 70 beats per minute and either on maximally tolerated doses of β-blockers or have a contraindication to β-blockers.
    [Show full text]
  • Poisoning – Investigative and Management Protocols
    UNIT-1 Management of Common Clinical Poisoning Dr. Pallav Shekhar Asstt. Professor Veterinary Medicine Suspection Common Symptoms exhibited by large no. of animals at a time. ➢ Sudden death ➢ Salivation ➢ Vomition ➢ Neurological signs ➢ Presence of mouldy feeds ➢ Presence of house hold waste and medicaments ➢ Sewage water contamination ➢ Presence of dead rat or rat wait ➢ Spray of insecticides, weedicides. ➢ Use of paint Principal of treatment Prevention of further exposure Alkalis are more dangerous than acids. Acids form insoluble acid proteinates and hence its effect is partially self limiting Alkalis form alkali proteinates along with soaps which will penetrate rapidly into tissues. Inhaled poisons can be eliminated by providing assisted ventilation. Topical applied toxicant can be removed by washing with plenty of water and soap. Skin contact can be eliminated by washing with plenty of water and soap if the poison is water soluble and with organic solvents like Benzene, alcohol if they are fat soluble Conti…. Clipping of hair or wool may be necessary Emesis is of value in dogs, cats and pigs if done within few hours of ingestion. Emesis is contraindicated when ▪ The swallowing reflex is absent ▪ Animal is convulsive ▪ Corrosive agent or volatile hydrocarbons or petroleum product ingested Conti…. Emetics: a) Oral: I. Syrup of ipecac; 10-20ml in dogs II. Hydrogen peroxide: 2ml/kg b) Parenteral: Apomorphine can be used in dogs at dosage of 0.05-0.1mg/kg Conti… Gastric lavage: This is done in mono-gastric animals and 10ml lavage fluid/kg body weight should be given. Potassium permanganate solution This is done with Endotracheal tube and stomach tube Conti… Insertion of stomach tube in cattle for gastric lavage Conti.
    [Show full text]
  • Bonviva, INN- Ibandronic Acid
    European Medicines Agency London, 1 September 2005 Doc.Ref.: EMEA/278873/2005 Bonviva International Nonproprietary Name: Ibandronic acid Following the procedure EMEA/H/C/501/X/01 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: [email protected] http://www.emea.eu.int EMEA 2005 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged 1 SCIENTIFIC DISCUSSION 1.1 Introduction and rationale The MAH submitted an extension application under Annex II, point 2 iii to Commission Regulation (EC) No 1085/2003 to request the approval of a 150 mg tablet as a monthly dosing regimen of ibandronate only for the indication of “treatment of osteoporosis in postmenopausal women, in order to reduce the risk of vertebral fractures”. This claim is based on the results of a phase III study MOBILE (BM16549) comparing 100 and 150 mg once monthly to 2.5 mg once daily. Due to the inconveniences associated with intake of oral bisphosphonates (i.e. fasting conditions, frequent upper gastrointestinal intolerance) that may result in poor compliance, it was considered desirable to develop a more convenient drug formulation. Hence a 150 mg once monthly oral regimen is expected to offer greater convenience to postmenopausal women when compared to the currently approved 2.5mg once daily tablet. The development programme No new pre-clinical pharmacodynamic and pharmacokinetic studies have been performed in addition to those included in the previous submission for ibandronate 2.5 mg daily oral tablets.
    [Show full text]
  • CCA Senior Care Options Formulary
    Commonwealth Care Alliance Senior Care Option HMO SNP 2021 List of Covered Drugs Formulary 30 Winter Street • Boston, MA 02108 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN This formulary was updated on 08/01/2021. For more recent information or other questions, please contact Senior Care Options Program (HMO SNP) Member Services, at 1-866-610-2273 or, for TTY users, 711, 8 a.m. – 8 p.m., 7 days a week, or visit www.commonwealthcaresco.org. HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Senior Care Options Program (HMO SNP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DO CUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN HPMS Approved Formulary File Submission ID 00021589, Version Number 13 Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us”, or “our,” it means Commonwealth Care Alliance. When it refers to “plan” or “our plan,” it means 2021 Senior Care Options Program. This document includes list of the drugs (formulary) for our plan which is current as of 08/01/2021. This formulary document applies to all SCO members. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy n etwork, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.
    [Show full text]
  • Automated Kappa Number Determination of Pulp
    Application Note YSI, a Xylem Brand • XA00077 Automated Kappa Number Determination of Pulp PULP & PAPER SERIES Introduction The Kappa number describes the Lignin content of pulp which gives information about the bleaching process of the pulp. The longer the pulp was cooked and bleached the lower the Kappa number is. For the determination of the Kappa number a sample weight adjusted to the expected result is chopped and inserted into a beaker, then 400 ml of water is added. The sample/water mixture is stirred for 10 minutes. Afterwards 50 ml of potassium permanganate (KMnO4, 0.02 mol/L) and 50 ml sulfuric acid (H2SO4, 2 mol/L) are added simultaneously. The mixture is stirred for another 10 minutes. The reaction is stopped by adding 10 ml potassium iodide (KI, 1mol/l). The excess of KMnO4 reacts with Iodide to Iodine, which is titrated with sodium thiosulfate (Na2S2O3, 0.2 mol/L). Chemical Equations: The weight is adjusted to a consumption of about 50% of the MnO4- . - + ➔ - Lignin + MnO4 + 4 H oxidised Lignin + MnO4 (excess) + MnO2 + 2 H2O The reaction is stopped by adding KI. - - + ➔ 2+ 2 MnO4 + 10 I + 16 H 2 Mn + 5 I2 + 8 H2O The formed Iodine is titrated with Na2S2O3. 2- ➔ - 2 S2O3 + I2 S4O6 + 2 I Calculation of the Kappa number: 1. Calculation of the consumed volume Va of KMnO4: 2. Calculation of a correction factor d, which corrects the consumption of permanganate depending on Va to a V1 – V2)c Va = consumption of 50%. 0.1 with d= 100.00093 (2Va – 50) In(10) • 0.00093 (2Va– 50)) V1 = Consumption of Na2S2O3 during blank titration = e V2 = Consumption of Na2S2O3 during sample titration c = Concentration of Na2S2O3 3.
    [Show full text]
  • Page 1 of 7 Analyst
    Analyst Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/analyst Page 1 of 7 Analyst 1 2 Analyst RSC Publishing 3 4 5 ARTICLE 6 7 8 9 Enhancing permanganate chemiluminescence 10 detection for the determination of glutathione and 11 Cite this: DOI: 10.1039/x0xx00000x 12 glutathione disulfide in biological matrices 13 14 a a a b 15 Zoe M. Smith, Jessica M. Terry, Neil W. Barnett, Laura J. Gray, Dean J. Received 00th January 2012, Wright c and Paul S. Francis a* 16 Accepted 00th January 2012 17 18 DOI: 10.1039/x0xx00000x Acidic potassium permanganate chemiluminescence enables direct post-column detection of 19 glutathione, but its application to assess the redox state of a wider range of biological fluids www.rsc.org/ 20 and tissues is limited by its sensitivity.
    [Show full text]
  • Profiling the Effects of Rifaximin on the Healthy Human Colonic Microbiota Using A
    bioRxiv preprint doi: https://doi.org/10.1101/828269; this version posted November 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 1 Profiling the effects of rifaximin on the healthy human colonic microbiota using a 2 chemostat model 3 4 Ines B. Mouraa#, Anthony M. Buckleya, Duncan Ewina, Emma Clarka, Suparna Mitraa, Mark 5 H. Wilcoxa,b, Caroline H. Chiltona 6 7 aLeeds Institute of Medical Research, Faculty of Medicine and Health, University of Leeds, 8 Leeds, UK; 9 bDepartment of Microbiology, Leeds Teaching Hospitals NHS Trust, The General Infirmary, 10 Leeds, UK 11 12 Keywords: Rifaximin, gut microbiota, chemostat model, 16S rRNA sequencing 13 14 # Corresponding Author: Dr Ines Moura 15 Healthcare Associated Infection Research Group 16 Leeds Institute of Medical Research 17 University of Leeds 18 Microbiology, Old Medical School 19 Leeds General Infirmary 20 Leeds LS1 3EX, UK 21 Tel +44 113 392 8663 22 Email: [email protected] 23 24 25 bioRxiv preprint doi: https://doi.org/10.1101/828269; this version posted November 1, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 2 26 Abstract 27 28 Rifaximin is a low solubility antibiotic with activity against a wide range of bacterial 29 pathogens.
    [Show full text]
  • Assessment at the Single-Cell Level Identifies Neuronal Glutathione Depletion As Both a Cause and Effect of Ischemia-Reperfusion Oxidative Stress
    The Journal of Neuroscience, May 6, 2015 • 35(18):7143–7152 • 7143 Neurobiology of Disease Assessment at the Single-Cell Level Identifies Neuronal Glutathione Depletion As Both a Cause and Effect of Ischemia-Reperfusion Oxidative Stress Seok Joon Won,1,2 Ji-Eun Kim,1,2 XGiordano Fabricio Cittolin-Santos,1,2 and XRaymond A. Swanson1 Departments of 1Neurology, University of California San Francisco, and 2Neurology Service, San Francisco Veterans Affairs Medical Center (SFVAMC), San Francisco, California 94121 Oxidative stress contributes to neuronal death in brain ischemia-reperfusion. Tissue levels of the endogenous antioxidant glutathione (GSH) are depleted during ischemia-reperfusion, but it is unknown whether this depletion is a cause or an effect of oxidative stress, and whether it occurs in neurons or other cell types. We used immunohistochemical methods to evaluate glutathione, superoxide, and oxidative stress in mouse hippocampal neurons after transient forebrain ischemia. GSH levels in CA1 pyramidal neurons were normally high relative to surrounding neuropil, and exhibited a time-dependent decrease during the first few hours of reperfusion. Colabeling for superoxide in the neurons showed a concurrent increase in detectable superoxide over this interval. To identify cause–effect relation- ships between these changes, we independently manipulated superoxide production and GSH metabolism during reperfusion. Mice in which NADPH oxidase activity was blocked to prevent superoxide production showed preservation of neuronal GSH content, thus demonstrating that neuronal GSH depletion is result of oxidative stress. Conversely, mice in which neuronal GSH levels were maintained by N-acetyl cysteine treatment during reperfusion showed less neuronal superoxide signal, oxidative stress, and neuronal death.
    [Show full text]
  • Rifaximin (XIFAXAN)
    Rifaximin (XIFAXAN) for Irritable Bowel Syndrome with Diarrhea National Drug Monograph March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Minimally absorbed, broad-spectrum antibacterial that inhibits bacterial RNA Action synthesis. The specific mechanism of action of rifaximin in irritable bowel syndrome (IBS) has not been determined. The most likely mechanism of rifaximin is reduction in overall bacterial load, particularly in the large bowel1; however, rifaximin also seems to modulate gut microenvironment and produce cytoprotective effects.2 Indication(s) Under Review in Treatment of IBS with diarrhea (IBS-D) in adults this Document Dosage Form(s) Under 550 mg tablet Review REMS REMS No REMS Postmarketing Requirements Pregnancy Rating No data available on pregnant women to inform any drug associated risks. Executive Summary Efficacy Rifaximin had a small, statistically significant beneficial effect relative to placebo in global IBS symptom response using pooled data: 40.7% vs. 31.7%, with a difference of 9.0 percentage points, p < 0.001; NNT = 11. Rifaximin had a small, statistically significant beneficial effect relative to placebo in terms of the response rate for adequate relief of bloating (the key secondary efficacy measure): 40.2% vs. 30.3%, difference of 9.9 percentage points, p < 0.001; NNT = 10 (pooled results).
    [Show full text]
  • Bisphosphonate Use in Patients with Breast Cancer
    Bisphosphonate use in patients with breast cancer Information for patients, relatives and carers For more information, please contact: Medicines Information Email: [email protected] York Hospital Medicines Information Tel: 01904 725960 Page 2 Contents Page Why have I been given this leaflet? ............................... 4 How is the treatment given? .......................................... 4 How long will I need to take the treatment for? .............. 6 Can I take other medicines at the same time? ............... 6 Who will prescribe the medication? ............................... 7 What if I am already on bisphosphonate treatment? ...... 7 Bisphosphonates are not licensed for reducing the risk of breast cancer recurrence. What does this mean? ...... 8 Are there any side effects? ............................................ 9 What is osteonecrosis? ............................................... 10 Are there any signs and symptoms I should look out for during treatment? ........................................................ 11 How can I decrease the risk of developing osteonecrosis of the jaw? ................................................................... 12 What do I need to do before starting treatment? .......... 13 Will I require any monitoring, or blood tests? ............... 14 Should I stop taking the bisphosphonate? ................... 14 Tell us what you think of this leaflet ............................. 15 Teaching, training and research ................................... 15 Patient Advice and Liaison Service (PALS) .................. 15 Page 3 Why have I been given this leaflet? You have been given this leaflet because you are going to be treated with a bisphosphonate medicine (zoledronic acid and/or ibandronic acid). In post-menopausal women, with early breast cancer, these drugs have been shown to reduce the risk of the disease recurring and increase length of life. How is the treatment given? The treatment will usually be provided as an oral tablet of ibandronic acid (one 50mg tablet taken once daily).
    [Show full text]